Dosing strategies for
Dosing
Genotype
Immunosuppression
Kidney transplant
Tacrolimus
Therapeutic drug monitoring
Journal
World journal of transplantation
ISSN: 2220-3230
Titre abrégé: World J Transplant
Pays: United States
ID NLM: 101608356
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
received:
30
08
2023
revised:
16
10
2023
accepted:
26
10
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
4
1
2024
Statut:
ppublish
Résumé
Tacrolimus extended-release tablets have been Food and Drug Administration-approved for use in the To obtain target trough concentrations of extended-release tacrolimus in Single-arm, prospective, single-center, open-label, observational study (ClinicalTrials.gov: NCT037 13645). Life cycle pharma tacrolimus (LCPT) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight. If weight is more than 120% of ideal body weight, an adjusted body weight was used. LCPT dose was adjusted to maintain tacrolimus trough concentrations of 8-10 ng/mL. Pharmacogenetic analysis of Mean time to therapeutic tacrolimus trough concentration was longer in Expression of
Sections du résumé
BACKGROUND
BACKGROUND
Tacrolimus extended-release tablets have been Food and Drug Administration-approved for use in the
AIM
OBJECTIVE
To obtain target trough concentrations of extended-release tacrolimus in
METHODS
METHODS
Single-arm, prospective, single-center, open-label, observational study (ClinicalTrials.gov: NCT037 13645). Life cycle pharma tacrolimus (LCPT) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight. If weight is more than 120% of ideal body weight, an adjusted body weight was used. LCPT dose was adjusted to maintain tacrolimus trough concentrations of 8-10 ng/mL. Pharmacogenetic analysis of
RESULTS
RESULTS
Mean time to therapeutic tacrolimus trough concentration was longer in
CONCLUSION
CONCLUSIONS
Expression of
Identifiants
pubmed: 38174147
doi: 10.5500/wjt.v13.i6.368
pmc: PMC10758687
doi:
Banques de données
ClinicalTrials.gov
['NCT00000037']
Types de publication
Journal Article
Langues
eng
Pagination
368-378Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Adam Diamond serves as an active member of the Veloxis Pharmaceuticals Speaker’s Bureau (honoraria provided).